Risk of myocardial infarction attributable to elevated levels of total cholesterol among hypertensives

被引:12
作者
Glazer, NL
Smith, NL
Heckbert, SR
Doggen, CJM
Lemaitre, RN
Psaty, BM
机构
[1] Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98101 USA
[2] Univ Washington, Dept Med, Seattle, WA USA
[3] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA
[4] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands
关键词
cholesterol; myocardial infarction; lipoproteins; hypertension; coronary disease;
D O I
10.1016/j.amjhyper.2004.12.015
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Although cholesterol is an important risk factor for coronary heart disease (CHD) among hypertensives, the burden of CHD among hypertensives that may be due to elevated cholesterol has not been well documented. This study aimed to estimate the proportion of incident myocardial infarction (MI) among hypertensives that may be attributable to elevated total cholesterol, and to investigate how well the National Cholesterol Education Program Adult Treatment Panel III (ATP III) classification method represents risk of MI among hypertensives. Methods: A population-based, case-control study of patients aged 30 to 79 years enrolled in a health maintenance organization, treated pharmacologically for hypertension, and who were not using lipid-lowering medication. Cases were diagnosed with an incident fatal or nonfatal MI between 1986 and 2000 (n = 1535). Controls were randomly sampled and frequency-matched to cases by sex, 10-year age category, and year of event (n = 3743). Subjects' most recent total cholesterol values were categorized according to ATP III guidelines. Results: Overall, 31% (95% confidence interval: 2339) of incident MIs among hypertensives could be explained by total cholesterol level above the optimal level of 200 mg/dL. Among participants in the highest ATP III risk stratum, 41% (95% confidence interval: 9-62) of the incident MIs were attributable to total cholesterol levels > 160 mg/dL, but total cholesterol >= 200 mg/dL accounted for the majority of these excess events. Conclusions: The ATP III risk stratification approach improves detection of the CHD burden due to elevated total cholesterol among hypertensives at highest risk. A strategy to improve cholesterol control in hypertensive patients might prevent a substantial part of the burden of morbidity and mortality from MI.
引用
收藏
页码:759 / 766
页数:8
相关论文
共 20 条
[1]   Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment [J].
Alderman, MH ;
Cohen, H ;
Madhavan, S .
JOURNAL OF HYPERTENSION, 1998, 16 (06) :761-769
[2]  
[Anonymous], 2001, STAT STAT SOFTW REL
[3]   Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes [J].
Cheung, BMY ;
Lauder, IJ ;
Lau, CP ;
Kumana, CR .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (05) :640-651
[4]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[5]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[6]   Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults - Findings from the National Health and Nutrition Examination Survey, 1999 to 2000 [J].
Ford, ES ;
Mokdad, AH ;
Giles, WH ;
Mensah, GA .
CIRCULATION, 2003, 107 (17) :2185-2189
[7]   Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care - The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) [J].
Furberg, CD ;
Wright, JT ;
Davis, BR ;
Cutler, JA ;
Alderman, M ;
Black, H ;
Cushman, W ;
Grimm, R ;
Haywood, LJ ;
Leenen, F ;
Oparil, S ;
Probstfield, J ;
Whelton, P ;
Nwachuku, C ;
Gordon, D ;
Proschan, M ;
Einhorn, P ;
Ford, CE ;
Piller, LB ;
Dunn, JK ;
Goff, D ;
Pressel, S ;
Bettencourt, J ;
deLeon, B ;
Simpson, LM ;
Blanton, J ;
Geraci, T ;
Walsh, SM ;
Nelson, C ;
Rahman, M ;
Juratovac, A ;
Pospisil, R ;
Carroll, L ;
Sullivan, S ;
Russo, J ;
Barone, G ;
Christian, R ;
Feldman, S ;
Lucente, T ;
Calhoun, D ;
Jenkins, K ;
McDowell, P ;
Johnson, J ;
Kingry, C ;
Alzate, J ;
Margolis, KL ;
Holland-Klemme, LA ;
Jaeger, B ;
Williamson, J ;
Louis, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (23) :2998-3007
[8]   HYPERLIPIDEMIA, HYPERTENSION, AND CORONARY HEART-DISEASE [J].
GOODE, GK ;
MILLER, JP ;
HEAGERTY, AM .
LANCET, 1995, 345 (8946) :362-364
[9]   MAXIMUM-LIKELIHOOD-ESTIMATION OF THE ATTRIBUTABLE FRACTION FROM LOGISTIC-MODELS [J].
GREENLAND, S ;
DRESCHER, K .
BIOMETRICS, 1993, 49 (03) :865-872
[10]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421